Biochemical markers of cardiac damage: From traditional enzymes to cardiac-specific proteins
Why the study?
Does the use of cardiac-specific proteins (troponin) improve the diagnosis and risk stratification of acute coronary syndromes compared to traditional enzymes?
Population
Patients with acute coronary syndromes, unstable angina, or acute myocardial infarction
Comparison
Cardiac biomarker testing vs Traditional enzymes (CK, CK-MB)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May inform ACS risk stratification; leaves open prospective validation against evolving assays.
Structured PICO
Does the use of cardiac-specific proteins (troponin) improve the diagnosis and risk stratification of acute coronary syndromes compared to traditional enzymes?
P
Population
Patients with acute coronary syndromes, unstable angina, or acute myocardial infarction
I
Intervention
Cardiac biomarker testing (specifically cardiac troponin)
C
Comparator
Traditional enzymes (CK, CK-MB)
O
Outcome
Diagnosis of acute myocardial infarction and risk stratification for death and AMIsurrogate
The transition from traditional enzymes to highly specific cardiac troponin assays has revolutionized the diagnosis, risk stratification, and therapeutic decision-making in acute coronary syndromes.
Cite This Study
Wu et al. (1999) studied this question.